Adding the numbers, since they settle part of this. Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with published data behind them are 5, 10 and 15mg.
One thing that is still open after NurseKim_ATL’s answer:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
raj_cambridge said:Practical numbers: half-life about 5 days, steady state 3 to 4 weeks, ladder 2.5 / 5 / 7.5 / 10 / 12.5 / 15mg, and the maintenance doses with…
There is a second half to this that has not been said yet. Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five. That matters when you are deciding whether a dose step has finished expressing itself.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.
Dr.SurgeonPGH said:Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.
I would rather be corrected than agreed with, if it comes to it.